Drugging the undruggable: Development of novel technologies to selectively regulate the expression of targets driving cancer and other diseases

Blancafort, Pilar (Chief Investigator)

School of Human Sciences

Status	Finished
Effective start/end date	1/01/13 → 31/12/18

Funding

Australian Research Council: A$188,830.00
Australian Research Council: A$188,830.00
Australian Research Council: A$188,830.00
Australian Research Council: A$188,830.00

Access Project

http://purl.org/au-research/grants/arc/FT130101767

7 Article
2 Review article

Manipulating the NKG2D Receptor-Ligand Axis Using CRISPR: Novel Technologies for Improved Host Immunity
Alves, E., McLeish, E., Blancafort, P., Coudert, J. D. & Gaudieri, S., 12 Aug 2021, In: Frontiers in Immunology. 12, 712722.
Research output: Contribution to journal › Article › peer-review

Open Access
1 Citation (Scopus)
Reprogramming the anti-tumor immune response via CRISPR genetic and epigenetic editing
Alves, E., Taifour, S., Dolcetti, R., Chee, J., Nowak, A. K., Gaudieri, S. & Blancafort, P., 11 Jun 2021, In: Molecular Therapy - Methods and Clinical Development. 21, p. 592-606 15 p.
Research output: Contribution to journal › Review article › peer-review

Open Access
4 Citations (Scopus)
Honeybee venom and melittin suppress growth factor receptor activation in HER2-enriched and triple-negative breast cancer
Duffy, C., Sorolla, A., Wang, E., Golden, E., Woodward, E., Davern, K., Ho, D., Johnstone, E., Pfleger, K., Redfern, A., Iyer, K. S., Baer, B. & Blancafort, P., 1 Sep 2020, In: npj Precision Oncology. 4, 1, 16 p., 24.
Research output: Contribution to journal › Article › peer-review

Open Access
39 Citations (Web of Science)